Marizyme, Inc. (MRZM)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Jul 25, 2025

Marizyme Company Description

Marizyme, Inc., a multi-technology life science company, engages in the research, manufacture, and commercialization of medical devices, diagnostics, and products to address clinical needs in the United States, Europe, and Asia.

The company operates as a medical technology company that delivers solutions for coronary artery bypass graft surgery.

Its product portfolio includes DuraGraft, a biocompatible intraoperative vascular graft storage and flushing solution; and Krillase, an enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, and dental care and thrombosi, as well as MATLOC 1, a lab on chip digital device, which is under development for screening of individuals at risk for the development of chronic kidney disease.

The company also engages in the development of MAR-FG-001, a fat grafting technology for fat grafting procedures.

The company was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018.

The company was incorporated in 2007 and is based in Jupiter, Florida.

Marizyme, Inc.
Marizyme logo
CountryUnited States
Founded2007
IndustryBiotechnology
SectorHealthcare
Employees13
CEODavid Barthel

Contact Details

Address:
555 Heritage Drive
Jupiter, Nevada 33458
United States
Phone561 935 9955
Websitemarizyme.com

Stock Details

Ticker SymbolMRZM
ExchangeOTCMKTS
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS5703721028
SIC Code2836

Key Executives

NamePosition
David L. Barthel M.B.A.Chief Executive Officer, Secretary and Director
George Kovalyov C.A., CPAChief Financial Officer, Treasurer and Director
Dr. Catherine J. Pachuk Ph.D.Executive Vice President and Chief Scientific Officer
Dr. Steven Scott Brooks FACC, M.B.A., M.D.Chief Medical Officer
Dr. Claudio Rigatto M.D.Chief Medical Officer of My Health Logic
Kari JacobsonController
Harrison Albert Ross C.F.A.Vice President of Finance